All In Biotech

Drug Trial Radar · NCT04711486

Evaluation of Safety of Contraloid Acetate in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease

A Single-centre, Randomized, Placebo-controlled, Double-blind, Phase 1b Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Contraloid Acetate in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease

Last checked: Nov 19, 2026Latest source record: Aug 23, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

19

Actual

Start

Dec 8, 2020

Primary completion

Jan 13, 2022

Study completion Jan 13, 2022

Sponsor

Lead sponsor
Charite University, Berlin, GermanyAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Berlin Institute of Health; Federal Agency for Disruptive Innovation - SPRIN-D
First posted
Jan 15, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Patients with mild cognitive impairment due to Alzheimer's disease (MCI due to AD) are at high risk to develop Alzheimer´s dementia. The therapeutic agent Contraloid has the potential to influence the chronic neurodegenerative process of AD. As Contraloid was so far only administered to healthy subjects, the rational of the proposed study is first to collect safety data in patients diagnosed with MCI due to AD, as the absorption, distribution, metabolism and excretion processes may be altered by disease, aging, comorbidities and concomitant drug therapies. Additionally, the design of a subsequent phase II study will be based on the data of this study. The results of the exploratory analyses will enable power calculations and the identification of the most useful and reliable biomarkers for the subsequent proof of concept phase II study.

Conditions

  • Mild Cognitive Impairment Due to Alzheimer's Disease

Interventions

  • Contraloid acetateDrug

    Oral administration of drug substance capsules

  • PlaceboDrug

    Oral administration of placebo without any exipients.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety: Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0Time frame: From baseline (day 1) to follow-up (day 56)
  2. Safety: Number of Participants with abnormal laboratory values (urinalysis, CBC, Quick, PTT, Creatinine, CK, CRP, ALT, AST)Time frame: From baseline (day 1) to follow-up (day 56)
  3. Safety: Number of Participants with abnormal ECG valuesTime frame: From baseline (day 1) to follow-up (day 56)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Charité University Medicine

    Berlin, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.